Loading...
Market
Outcome of TROPiCS-04 study publication by mid-2025?
2
Resolution / Starting Odds
Positive results for another indication • 25%
Negative results across all indications • 25%
Inconclusive results • 25%
Not published by this date • 25%
Publication in a peer-reviewed medical journal
Story
Gilead to Withdraw US Approval for Trodelvy in Urothelial Cancer on Friday
Oct 18, 2024, 01:00 PM
Gilead Sciences has announced its decision to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy) for the treatment of adults with locally advanced or metastatic urothelial cancer. This decision, announced on Friday, follows consultations with the FDA and the results from the TROPiCS-04 study, which did not meet the overall survival endpoint. The withdrawal specifically affects patients who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. Other indications for Trodelvy remain unaffected. The drug was used in previously treated bladder cancer patients.
View original story
Similar markets
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial halted • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial extended • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
